Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

Cool photo. The Lancet is our holy grail of peer-reviewed medicine. There is no doubt that any respiratory medicine widely utilized is going to draw in billions.

I think that it's important to draw attention to the fact that ifenprodil is being trialed for treatment of acute lung disease. Yes, we are treating COVID patients but the pathology we are treating is acute respiratory distress syndrome secondary to acute lung disease with leaky microvasculature and increased inflammatory cells with proinflammatory cytokines. The reason this is important, is because influenza has the same underlying pathology.

So translation: if this drug works for COVID... influenza trial will follow. If it works for covid, it will almost certainly work for influenza (since same pathology). As such, we will be scoring bigger than most realize.